Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 10:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–45 of 21 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: glyburide Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Glyburide/Metformin HCl 5 mg/500 mg Tablets Under Fasting Conditions

NCT00865436
View directory record Official record
Conditions
Healthy
Interventions
Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg, CLUCOVANCE® 5 mg/500 mg Tablets, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 16, 2010 · Synced Sep 23, 2026, 10:06 AM EDT
Completed Phase 3 Interventional

A Research Study to Determine the Safety and Efficacy of Glucovance Compared to Metformin and Glyburide in Children and Adolescents With Type 2 Diabetes.

NCT00035542
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
Glucovance (metformin HCl/glyburide), metformin HCl, glyburide
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
9 Years to 16 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
50
States / cities
Birmingham, Alabama • Tucson, Arizona • Beverly Hills, California + 43 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2011 · Synced Sep 23, 2026, 10:06 AM EDT
Completed Not applicable Interventional

A Prospective Trial to Assess Cost and Clinical Outcomes of a Clinical Pharmacogenomic Program

NCT02297126
View directory record Official record
Conditions
Adverse Drug Reaction
Interventions
Pharmacogenetic Intervention Arm (pharmacogenetic testing)
Other
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
4,465 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jan 7, 2021 · Synced Sep 23, 2026, 10:06 AM EDT
Not listed No phase listed Observational

BESTMED: Observational Evaluation of Second Line Therapy Medications in Diabetes

NCT05161429
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
DPP4, GLP-1 receptor agonist, Basal Insulin, SLGT2, SU
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
30 Years and older
Enrollment
550,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
5
States / cities
Wilmington, Delaware • Lexington, Kentucky • Boston, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 21, 2023 · Synced Sep 23, 2026, 10:06 AM EDT
Active, not recruiting No phase listed Observational

Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study

NCT05220917
View directory record Official record
Conditions
Cardiovascular Events, Type2 Diabetes, Renal Disease
Interventions
SGLT2 inhibitor, DPP-4 inhibitor, GLP-1RA, 2nd generation SU
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
781,430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 12, 2026 · Synced Sep 23, 2026, 10:06 AM EDT
Completed Phase 3 Interventional

Determine Whether Glycemic Control is Different Between Lantus & a 3rd Oral Agent When Failure With Other Treatment

NCT00046462
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Lantus (insulin glargine [rDNA origin] injection), Metformin, Glyburide, Thiazolidinedione
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years to 79 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Bridgewater, New Jersey
Source: ClinicalTrials.gov public record
Updated Jan 10, 2011 · Synced Sep 23, 2026, 10:06 AM EDT
Completed Phase 4 Interventional

A Research Study to Assess the Mechanism By Which Glucovance, Metformin, and Glyburide Work To Control Glucose Levels In Patients With Type 2 Diabetes

NCT00035568
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
Glucovance (metformin HCl/glyburide), or Metformin HCl alone, or Glyburide alone.
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
20 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
9
States / cities
Little Rock, Arkansas • Los Angeles, California • Chicago, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2011 · Synced Sep 23, 2026, 10:06 AM EDT
Completed Phase 4 Interventional

Effect of Repaglinide on Postprandial Lipemia in Type 2 Diabetes

NCT01605773
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 2
Interventions
repaglinide, glyburide
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 19, 2017 · Synced Sep 23, 2026, 10:06 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Lixisenatide Versus Placebo on Top of Basal Insulin and/or Oral Antidiabetic Treatment in Older Type 2 Diabetic Patients

NCT01798706
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Lixisenatide (AVE0010), Placebo, Antidiabetic background therapy
Drug
Lead sponsor
Sanofi
Industry
Eligibility
70 Years and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
14
States / cities
La Jolla, California • Norwalk, California • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 17, 2017 · Synced Sep 23, 2026, 10:06 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Treatment of Mild Gestational Diabetes With Glyburide Versus Placebo

NCT00744965
View directory record Official record
Conditions
Mild Gestational Diabetes
Interventions
Glyburide, Placebo
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
16 Years to 45 Years · Female only
Enrollment
395 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2016
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Mar 11, 2020 · Synced Sep 23, 2026, 10:06 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Glyburide Advantage in Malignant Edema and Stroke Pilot

NCT01268683
View directory record Official record
Conditions
Ischemic Stroke
Interventions
Glyburide for Injection
Drug
Lead sponsor
Remedy Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
4
States / cities
Chicago, Illinois • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Sep 23, 2026, 10:06 AM EDT
Terminated Early Phase 1 Interventional

Glyburide vs Glucovance in the Treatment of GDM

NCT02726490
View directory record Official record
Conditions
Gestational Diabetes
Interventions
Glyburide, Glucovance
Drug
Lead sponsor
Texas Tech University Health Sciences Center, El Paso
Other
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Oct 11, 2020 · Synced Sep 23, 2026, 10:06 AM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of BIIB093 in Participants With Brain Contusion

NCT03954041
View directory record Official record
Conditions
Brain Contusion
Interventions
BIIB093, Placebo
Drug
Lead sponsor
Remedy Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
92 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
25
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 21 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2024 · Synced Sep 23, 2026, 10:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Metformin Compared to Glyburide in Gestational Diabetes

NCT00965991
View directory record Official record
Conditions
Gestational Diabetes
Interventions
metformin, Glyburide
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
13 Years and older · Female only
Enrollment
149 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2023
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Sep 23, 2026, 10:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Glyburide Healthy Volunteer Study

NCT01716338
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Glyburide, Placebo
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 40 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 15, 2014 · Synced Sep 23, 2026, 10:06 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Glyburide Compared to Insulin in the Management of White's Classification A2 Gestational Diabetes

NCT00160485
View directory record Official record
Conditions
Gestational Diabetes
Interventions
Glyburide, Insulin
Drug
Lead sponsor
Tripler Army Medical Center
Federal
Eligibility
18 Years and older · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2010
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Feb 10, 2014 · Synced Sep 23, 2026, 10:06 AM EDT
Completed Phase 3 Interventional

PPAR-COMBO With Sulfonylurea

NCT00162175
View directory record Official record
Conditions
Metabolics Diabetes Nos
Interventions
Muraglitazar
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
534 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
74
States / cities
Anniston, Alabama • Hoover, Alabama • Huntsville, Alabama + 71 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2010 · Synced Sep 23, 2026, 10:06 AM EDT
Completed Phase 3 Interventional

Diabetes Study With Rosiglitazone Monotherapy Versus Metformin Or Glyburide/Glibenclamide

NCT00279045
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Rosiglitazone, glyburide, metformin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
30 Years to 75 Years
Enrollment
4,426 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
178
States / cities
Anniston, Alabama • Birmingham, Alabama • Mesa, Arizona + 132 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2017 · Synced Sep 23, 2026, 10:06 AM EDT
Completed Phase 2 Interventional

Glyburide (RP-1127) for Traumatic Brain Injury (TBI)

NCT01454154
View directory record Official record
Conditions
Traumatic Brain Injury
Interventions
Glyburide, Placebo
Drug
Lead sponsor
Remedy Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
4
States / cities
San Diego, California • Baltimore, Maryland • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2024 · Synced Sep 23, 2026, 10:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Relative Bioavailability Study of Glyburide/Metformin HCl 5 mg/500 mg Tablets Under Fasting Conditions

NCT00865241
View directory record Official record
Conditions
Healthy
Interventions
Glyburide and Metformin Hydrochloride Tablets 5 mg/500 mg, CLUCOVANCE® 5 mg/500 mg Tablets, single dose
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2002
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Aug 16, 2010 · Synced Sep 23, 2026, 10:06 AM EDT
Completed Phase 3 Interventional Results available

Study of Alogliptin Combined With Sulfonylurea in Subjects With Type 2 Diabetes Mellitus.

NCT00286468
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Alogliptin and glyburide, Glyburide
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 80 Years
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
54
States / cities
Birmingham, Alabama • Peoria, Arizona • Phoenix, Arizona + 51 more
Source: ClinicalTrials.gov public record
Updated Feb 2, 2012 · Synced Sep 23, 2026, 10:06 AM EDT